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Summary
Background Seasonal influenza virus is a common cause of acute lower respiratory infection (ALRI) in young children. 
In 2008, we estimated that 20 million influenza-virus-associated ALRI and 1 million influenza-virus-associated severe 
ALRI occurred in children under 5 years globally. Despite this substantial burden, only a few low-income and middle-
income countries have adopted routine influenza vaccination policies for children and, where present, these have 
achieved only low or unknown levels of vaccine uptake. Moreover, the influenza burden might have changed due to 
the emergence and circulation of influenza A/H1N1pdm09. We aimed to incorporate new data to update estimates of 
the global number of cases, hospital admissions, and mortality from influenza-virus-associated respiratory infections 
in children under 5 years in 2018.
Methods We estimated the regional and global burden of influenza-associated respiratory infections in children under 
5 years from a systematic review of 100 studies published between Jan 1, 1995, and Dec 31, 2018, and a further 
57 high-quality unpublished studies. We adapted the Newcastle-Ottawa Scale to assess the risk of bias. We estimated 
incidence and hospitalisation rates of influenza-virus-associated respiratory infections by severity, case ascertainment, 
region, and age. We estimated in-hospital deaths from influenza virus ALRI by combining hospital admissions and 
in-hospital case-fatality ratios of influenza virus ALRI. We estimated the upper bound of influenza virus-associated 
ALRI deaths based on the number of in-hospital deaths, US paediatric influenza-associated death data, and population-
based childhood all-cause pneumonia mortality data in six sites in low-income and lower-middle-income countries.
Findings In 2018, among children under 5 years globally, there were an estimated 109∙5 million influenza virus 
episodes (uncertainty range [UR] 63∙1–190∙6), 10∙1 million influenza-virus-associated ALRI cases (6∙8–15∙1); 
870 000 influenza-virus-associated ALRI hospital admissions (543 000–1 415 000), 15 300 in-hospital deaths 
(5800–43 800), and up to 34 800 (13 200–97 200) overall influenza-virus-associated ALRI deaths. Influenza virus 
accounted for 7% of ALRI cases, 5% of ALRI hospital admissions, and 4% of ALRI deaths in children under 5 years. 
About 23% of the hospital admissions and 36% of the in-hospital deaths were in infants under 6 months. About 
82% of the in-hospital deaths occurred in low-income and lower-middle-income countries.
Interpretation A large proportion of the influenza-associated burden occurs among young infants and in low-income 
and lower middle-income countries. Our findings provide new and important evidence for maternal and paediatric 
influenza immunisation, and should inform future immunisation policy particularly in low-income and middle-
income countries.
Funding WHO; Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Acute lower respiratory infections (ALRIs) are one of the 
leading causes of morbidity and mortality in children 
globally, accounting for 16% of mortality in children 
under 5 years in 2015.1 We previously estimated that, in 
2015, 138 million ALRI cases, 22 million cases of severe 
ALRI, and 0∙9 million ALRI deaths occurred globally.2 
Seasonal influenza virus is an important pathogen 
associated with ALRI, detected in 3–7% of ALRI hospital 
admissions in children under 5 years.3,4 We previously 
estimated that 20 million episodes of influenza-
virus-associated ALRI, 1 million episodes of severe 
influenza-virus-associated ALRI and 28 000–111 000 
influenza-virus-associated ALRI deaths occurred in 
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children under 5 years in 2008.5 Despite this substantial 
burden, only 10% of low-income countries (LICs) and 
lower-middle-income countries (LMICs) have adopted 
national maternal or child influenza immunisation 
policies (13% for pregnant women) and, where present, 
most have achieved only low or unknown levels of 
vaccine uptake.6-9 Influenza burden might have changed 
since we calculated these previous estimates due to the 
emergence and circulation of influenza A/H1N1pdm09. 
We aimed to incorporate new data to estimate the global 
number of cases, hospitalisations, and mortality from 
influenza-virus-associated ALRI in children under 
5 years in 2018. These updated global burden estimates 
should inform the development of influenza immuni-
sation policies and resource allocation decisions for 
young children.
Methods
Systematic review
We did a systematic review of the influenza-virus-
associated disease burden in children under 5 years 
(appendix pp 4–6). We updated our previous review by 
searching Medline (Ovid), Embase (Ovid), Global 
Health (Ovid), CINAHL, Web of Science, and the Global 
Health Library for studies published between Jan 1, 2009 
and Dec 31, 2018; earlier studies published from 1995 
onwards in the previous review were also included.5 We 
also did our systematic review in three Chinese 
databases (CNKI, Wanfang, and Chongqing VIP), 
searching for studies published between Jan 1, 1995, 
and Dec 31, 2018. To search the grey literature, we also 
did broad searches through Google. No language or 
publication restrictions were applied, and reviewers 
screened the titles and abstracts for eligibility, and 
extracted data independently. Articles in non-Chinese or 
non-English were translated into English using Google 
Translate. Four reviewers (XW, YL, MR, and AC) 
screened the English-language databases. Two reviewers 
(XW and YL) screened the Chinese-language databases. 
Disagreements were resolved by HN.
We included studies that were published between 
Jan 1, 1995, and Dec 31, 2018, and reported any of 
Research in context
Evidence before this study
We previously estimated that in 2008, influenza virus was 
associated with 13% of all childhood acute lower respiratory 
infections ALRI episodes, and 2–10% of all childhood ALRI 
deaths, with 99% of these deaths occurring in developing 
countries. Since then, additional studies have estimated 
influenza-virus-associated or influenza-virus-attributable 
morbidity and mortality burden in children under 5 years 
globally using different methods. One systematic review (by the 
Global Respiratory Hospitalizations—Influenza Proportion 
Positive Working Group) estimated that there were 870 000 
(95% CI 610 000–1 237 000) influenza-virus-associated ALRI 
hospitalisations in 2012 by applying the percentage of 
hospitalised children with ALRI positive for influenza virus to 
all-cause ALRI hospitalisations. Another study (by the Global 
Seasonal Influenza-associated Mortality Collaborator Network) 
estimated that there were 44 888 (95% credible interval 
9243–105 690) influenza-virus-associated respiratory deaths in 
2015 by use of excess respiratory mortality regression models 
on vital deaths records and influenza surveillance data. The 
third study (by the Institute for Health Metrics and Evaluation) 
estimated that there were about 8 million influenza-virus-
attributable ALRI cases, 2 200 000 influenza-virus-attributable 
ALRI hospitalisations, and 23 400 influenza-virus-attributable 
ALRI deaths in children under 5 years in 2017; the mortality 
estimate was modelled on all-cause ALRI deaths, the population 
attributable fraction for influenza virus in ALRI, and the ratio of 
case-fatality between viral ALRI and bacterial ALRI.
Added value of this study
Our review was based on laboratory-confirmed influenza 
infection morbidity and mortality data. We incorporated an 
increased number of studies (157 studies in total, of which 
78% were new data) compared to our previous analysis in 
2008. Moreover, 36% of these studies were high quality 
unpublished data, and 39% from low-income and lower-
middle income countries. The emergence and circulation of 
influenza A/H1N1pdm09 might have impacted the influenza 
burden globally. Inclusion of new data enabled us to provide 
new evidence in the era with the new influenza virus’ 
circulation, informing future immunisation policy, especially in 
low-income and lower middle-income countries. In this review, 
we reported influenza-virus-associated respiratory disease 
burden by severity and by World Bank income level for age 
groups relevant for vaccine policy decisions. We estimated that 
influenza virus was associated with 7% of ALRI cases 
(10∙1 million cases [uncertainty range (UR) 6∙8–15∙1]), 5% of 
ALRI hospitalisations (870 000 [UR 543 000–1 415 000]), and 
4% of ALRI deaths (34 800 [UR 13 200–97 200]) in children 
under 5 years. About 23% of hospitalisations and 36% of 
in-hospital deaths were in infants younger than 6 months. 
About 82% of in-hospital deaths occurred in low-income and 
lower-middle income countries.
Implications of all the available evidence
Our updated review reports new influenza-virus-associated 
ALRI morbidity and mortality estimates in the era with the 
circulation of influenza A/H1N1pdm09. A large proportion of 
influenza-associated burden occurs among young infants and 
among children in low-income and lower-middle-income 
countries. Our findings provide new and important evidence for 
maternal and paediatric influenza immunisation, and should 
inform future immunisation policy particularly in low-income 
and middle-income countries.
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the following data in children younger than 5 years: 
community incidence rates of respiratory diseases (eg, 
influenza-like-illness, ALRI, and more severe infections) 
with laboratory-confirmed influenza virus; hospitalisation 
rates of ALRI, ALRI with hypoxaemia, or very severe ALRI 
with laboratory-confirmed influenza virus; in-hospital 
case-fatality ratios (hCFRs) of ALRI with laboratory-
confirmed influenza virus.
Studies had to use a clearly defined case definition for 
specimen collection and testing, and studies that 
reported incidence and hospitalisation rate data had to 
show data for at least one complete calendar year (or at 
least one full influenza season if in a temperate region). 
We included hCFR data for any length of period.
We excluded studies: without a clear denominator 
population at risk (limited to those reporting incidence 
and hospitalisation rate data); those in which influenza 
was studied as a co-infection rather than the primary 
outcome (ie, only including cases tested negative for 
other pathogens, or only including cases co-infected with 
influenza virus and other pathogens); reporting modelled 
burden estimates; studies in which influenza virus 
infections were diagnosed based on serology alone (strict 
require ment on sampling timing and serial sampling; 
poor sensitivity); explicitly stating that they included any 
nosocomial infections in the numerator; only including 
population subgroups with high-risk conditions; or 
reporting data from the pandemic period (2009–10 
season in temperate regions and the year of 2009 in 
tropical regions), or reporting combined data for the non-
pandemic and pandemic periods.
Identification and assembly of high-quality unpublished 
data
The Respiratory Virus Global Epidemiology Network is a 
collaboration network including more than 70 investigator 
groups working on respiratory viral infections (eg, 
respiratory syncytial virus and influenza virus) and 
provided additional unpublished data to supplement 
the systematic review.10 We formulated common case 
definitions and shared data through agreed common 
approaches to data analysis. Other investigators with 
relevant data were also invited to contribute data and 
participate in the analysis.
Definitions
A study was defined as a dataset from one site in 
one published paper or from one research group in the 
collaboration network. Similar to our previous analysis, 
we used separate case definitions for community-based 
studies with active case ascertainment and hospital-based 
studies with passive case ascertainment (appendix p 2).10 
Figure 1: Approaches for estimation of global influenza virus morbidity and mortality in children under 5 years
We report the number of influenza virus episodes and the number of cases of influenza-virus-associated ALRIs, global influenza-virus-associated-ALRI hospitalisations, 
and global estimates of influenza-virus-associated ALRI deaths in hospital and overall deaths (in community). This figure summarises our approach for each outcome and 
also shows how they relate to each other. Global estimates of hospitalisations for influenza virus ALRI were estimated by applying hospitalisation rates to population 
estimates (2018). Influenza-virus-associated ALRI in-hospital deaths were estimated by combining in-hospital case fatality ratios (hCFRs) for cases and hospitalisations. 
The inflation factor was estimated using three approaches (appendix pp 20–26), and we determined to use the most conservative estimate to calculate the number of 
overall deaths (appendix pp 20–26). A detailed description of imputation is in the appendix (p 28). ALRI=d acute lower respiratory infection. 
Denominator and case number
imputation for missing 0–59 months
Influenza virus associated-episodes 
and -ALRI incidence rate meta-
estimates by region 
Global influenza virus associated-
episodes and -ALRI cases
Influenza virus associated-episodes 
and -ALRI cases by region
Systematic review of hospital-based
studies reporting hospitalisation 
rates of influenza virus associated-
ALRI 
Denominator and case number
imputation for missing 0–59 months
Influenza virus associated-ALRI 
hospitalisation rate meta-estimates 
by age and region
Global hospitalisations of influenza 
virus associated-ALRI 
Hospitalisations of influenza virus 
associated-ALRI by age and region
Systematic review of studies
reporting hCFRs of influenza virus 
associated-ALRI
Meta-estimates of hCFRs for 
influenza virus associated-ALRI by 
age and region
Global influenza virus associated-
ALRI in-hospital deaths
Influenza virus associated-ALRI 
in-hospital deaths by age and region
Population-based pneumonia
mortality data 
Inflation factor in developing and
industrialised countries
Global overall influenza virus 
associated-ALRI deaths
Global and regional influenza virus 
associated-episodes and influenza 
virus associated-ALRI cases
Global and regional influenza virus 
associated-ALRI hospitalisations
Population estimates
Systematic review of community-
based studies reporting incidence
rates of influenza virus associated-
episodes, and influenza virus 
associated-ALRI
Global and regional influenza virus associated-ALRI deaths
Articles
e500 www.thelancet.com/lancetgh   Vol 8   April 2020
Ministry of Health, Santiago, 
Chile (V Sotomayor MPH); 
Division of Global Health 
Protection, Thailand Ministry 
of Public Health; US CDC 
Collaboration, Nonthaburi, 
Thailand (S Thamthitiwat MD); 
Department of Medical 
Virology, National Health 
Laboratory Service and School 
of Pathology, Faculty of Health 
Sciences, University of the 
Witwatersrand, Johannesburg, 
South Africa 
(F K Treurnicht PhD); African 
Population & Health Research 
Center, Nairobi, Kenya 
(M Wamukoya MPH); 
Department of Pediatric 
Infectious Diseases, Institute of 
Tropical Medicine, Nagasaki 
University, Nagasaki, Japan 
For community-based studies, the 2005 WHO Integrated 
Management of Childhood Illnesses case definition11 for 
clinical pneumonia was used to define ALRI since these 
definitions were used in most included community 
studies and have been widely used as indications for 
the treatment of pneumonia. Two further severity levels 
for community-based studies included severe ALRI 
(ie, ALRI with chest wall indrawing) and very severe ALRI 
(ie, ALRI with any general danger signs).11 For hospital-
based studies, where diagnoses were based on physicians’ 
clinical judgment, we defined hospitalised ALRI as 
the physician-confirmed diagnosis of ALRI where 
hospitalisation was required or recommended. We 
defined two further severity levels: ALRI with hypoxaemia 
(SpO2 <90%), and very severe ALRI (ie, children 
hospitalised with ALRI with any general danger signs,11 
admitted to intensive care units [ICUs], or requiring 
mechanical ventilation).
Assessment of risk of biases
We adapted the Newcastle-Ottawa Scale to assess the risk 
of bias in included studies.12 The modified scale contains 
seven domains: study design, adjustment for health 
utilisation, patient groups excluded, case definition, 
sampling strategy (ie, how cases were selected for sample 
collection and testing), diagnostic testing, and 
hypoxaemia ascertainment (appendix pp 9–10). Critical 
assessments on the risk of bias (high or low) were made 
separately for each domain.
Statistical analysis
We extracted the number of cases and scaled the 
population-at-risk for the proportion of eligible patients 
who were tested per study where available (appendix 
p 27). We did stratified analyses by case ascertainment, 
severity, developing status according to UNICEF 
definitions, World Bank income level (LICs, LMICs, 
upper-middle-income [UMICs],  and high-income 
countries [HICs]), and three non-overlapping age bands 
(0–5 months, 6–11 months, and 12–59 months).13,14 Due to 
the small number of studies in LICs (appendix pp 7–8), 
we combined LICs and LMICs (as LMICs) when reporting 
burden estimates. We imputed rates for missing 
0–59 months using a multiple imputation approach to 
allow for the uncertainty in missing data, and imputed 
missing population-at-risks according to the population 
structure by country income group based on WHO life 
tables (appendix pp 28–29).15–17
Figure 1 summarises our approach for burden 
estimation. We estimated incidence rates, hospital 
admission rates, and hCFRs of influenza virus-
associated respiratory infections using a generalised 
linear mixed model.18 In our previous analysis, we used a 
classic random-effect model. Compared with the 
previous model, the current model has an advantage in 
analysing studies with few events and does not require 
adding a continuity correction in case of zero events. 
The meta-estimates of influenza-virus-associated ALRI 
hospitalisation rate from the mixed regression model 
were similar to those from the classic random-effects 
model for most age groups, except for infants under 
3 months (appendix pp 62–63). We estimated influenza-
virus-associated ALRI cases (severe and very severe) and 
hospitalisations as described previously.10 Incidence 
rates and hospitalisation rates were applied to the UN 
population estimates for 2018.19,20 The burden estimates 
and uncertainty ranges (URs) were calculated using 
Monte Carlo simulation, with the median value of 
10 000 samples simulated from a log-normal distribution 
as the point estimate and the 2∙5th and 97∙5th percentiles 
as the 95% UR.10 We included all studies in the main 
analyses.
Previous evidence suggested that HIV infection21 was an 
important risk factor for influenza hospitalisation and 
death, and that the receipt of pneumococcal conjugate 
vaccine (PCV)22–25 was associated with reduced risk of 
Figure 2: Flow diagram for selection of studies on seasonal influenza
For multisite papers, the site-specific data were extracted where available and were analysed as one study; in this 
way 100 studies were extracted from 89 papers. One study could provide data on multiple outcomes among 
the same population; therefore the total number of studies was greater than the sum of studies by outcomes. 
RSV GEN=Respiratory Virus Global Epidemiology Network. IFV=influenza virus. ALRI=acute lower respiratory 
infection.
8367 records screened 
530 records identified through other sources13 123 records identified through database search 
1133 full-text papers assessed for eligibility
7234 records excluded as not relevant to topic
5286 duplicates removed
89 papers included (100 studies)
Studies with incidence rates
27 IFV-episodes
12 IFV-ALRI
14 IFV-severe ALRI
4 IFV-very severe ALRI
Studies with hospitalisation rates
96 IFV-ALRI
17 IFV-ALRI with hypoxaemia
31 IFV-very severe ALRI
66 studies reported in-hospital
case fatality ratios (hCFRs) 
1044 full-text papers excluded
 151 related to 2009 influenza pandemic
 5 conference abstracts
 102 duplicate data
 10 no rate for full influenza seasons or
for complete calendar years
 26 no denominator
 43 reporting modelled estimates
 707 without relevant data for 0–59 months
57 studies from RSV GEN 
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hospitalisation and death. As sensitivity analyses, we 
stratified data to assess how global influenza-virus-
associated ALRI hospitalisations and in-hospital deaths 
were affected by (1) study bias (eg, a low risk of bias in 
sampling strategy), (2) low or high PCV coverage setting 
(≤60% or >60% in general population), and (3) low or high 
maternal HIV burden setting (according to the UNAIDS 
Global Plan; appendix pp 11–17).26,27 We considered 
maternal HIV burden a good proxy of HIV burden in 
young children because mother-to-child transmission 
of HIV accounted for most HIV infection in young 
children.28 Results of sensitivity analyses are in the 
appendix (pp 11–19; 22–24). We also reported estimates for 
2015 to enable comparisons with the 2015 estimates of 
respiratory syncytial virus ALRI burden (appendix, p 19).
We estimated in-hospital deaths by combining 
the influenza-virus-associated ALRI hospitalisations 
and hCFR meta-estimates as described previously.10 
We included all studies in the main analysis of 
influenza-virus-associated ALRI in-hospital deaths, and 
conducted the same sensitivity analyses as described 
above for influenza-virus-associated ALRI hospitalisations 
(appendix pp 12–13, 16–17). For overall influenza-virus-
associated ALRI mortality analysis, we invited investigators 
from the International Network for the Demographic 
Evaluation of Populations and their Health (INDEPTH) 
Network who had health and demographic surveillance 
data for defined populations to provide the numbers of 
pneumonia deaths occurring in and out of hospital.29 We 
identified six sites (in Mozambique, Kenya, South Africa, 
Burkina Faso, and Ghana) with eligible data (appendix 
p 20). For industrialised countries, the US Influenza-
Associated Pediatric Mortality Surveillance System reports 
the most relevant data to our knowledge: location-specific 
deaths for children under 18 years with laboratory-
confirmed influenza virus infection.30 For our analysis, we 
extracted the number of influenza-virus-associated 
paediatric deaths occurring in communities, emergency 
depart ments, and hospitals over 14 years during 2004–18 
(excluding the pandemic year of 2009–10). Location-
specific data on deaths among children aged 0–4 years 
were unavailable. We assumed health-care access in the 
USA was similar to other industrialised countries.
We estimated overall influenza-virus-associated 
ALRI deaths by combining in-hospital deaths and the 
median inflation factor of overall influenza-virus-
associated ALRI deaths versus in-hospital deaths.10,31 For 
industrialised countries we calculated the inflation factor 
directly by dividing the total number of paediatric 
influenza-virus-associated deaths by the number of 
deaths occurring in hospitals in the USA.30 For 
developing countries where the number of influenza-
virus-specific deaths by location was unavailable, we 
divided the total number of pneu monia deaths by 
in-hospital pneumonia deaths, and used the median 
value across countries to represent the inflation factor 
for influenza-virus-specific ALRI deaths. Using this 
approach, we assumed that the relative contribution of 
influenza to ALRI deaths was the same for hospital and 
community settings. In sensitivity analyses we used two 
alternative approaches (approaches 2 and 3 in appendix 
pp 20–26). Approach 2 and 3 shared the same strategy in 
applying the proportion of influenza-virus-associated 
ALRI deaths among all-cause ALRI deaths to national 
all-cause pneumonia deaths, then dividing the national 
number of influenza-virus-associated ALRI in-hospital 
deaths, to back-calculate the inflation factor.
All analyses were done in R version 3.5.2, specifically 
the metafor package.32,33 This study was done and 
reported in accordance with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) 
recommendations and the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) 
statement (appendix pp 72–74).34,35
Figure 3: Location of included studies on influenza-virus-associated acute lower respiratory infection in children younger than 5 years
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Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. XW and HN (the corresponding author) had 
full access to all the data in the study and HN had final 
responsibility for the decision to submit for publication.
Results
During 1995–2018, we identified 157 studies (123 new 
studies) providing data on community incidence, 
hospitalisation rates, and hCFRs (figure 2). Of these 
studies, 57 were unpublished and 100 were from 
published literature (89 papers). 106 studies (68%) were 
from developing countries; 14 studies (9%) were from 
LICs, 48 (31%) from LMICs, 29 (18%) from UMICs, 
62 (39%) from HICs, and four studies from multiple 
countries from different country income groups 
(appendix pp 7–8; 30–58). Figure 3 shows where the 
included studies were conducted.
38 community-based studies reported incidence. 
27 studies reported incidence of influenza virus episodes 
for 0–59 months, and 12 studies reported incidence 
for influenza-virus-associated ALRI cases (appendix 
pp 30–32). In 2018 among children under 5 years, we 
estimated 109∙5 million (UR 63∙1–190∙6) influenza virus 
episodes and 10∙1 million (UR 6∙8–15∙1) influenza-virus-
associated ALRI cases globally. We were unable to 
estimate the burden in UMICs due to the scarcity of 
studies. We estimated 1∙4 million (UR 0∙6–3∙4) severe 
influenza-virus-associated ALRI cases, and 0∙4 million 
LMICs UMICs HICs Developing countries Industrialised 
countries
Global burden estimates*
Influenza virus episodes
Age 0–5 months
Studies 9 1 0 10 ∙∙ ∙∙
Incidence (per 1000 children per 
year)†
80∙2 (40∙9–151∙6) ∙∙ ∙∙ 80∙8 (44∙2–143∙1) ∙∙ ∙∙
Episodes (1000s) 3552 (1848–6831) ∙∙ ∙∙ 5018 (2792–9023) ∙∙ ∙∙
Age 6–11 months
Studies 2 1 0 2 ∙∙ ∙∙
Incidence (per 1000 children per year) 165∙9 (93∙2–277∙8) ∙∙ ∙∙ 164∙8 (92∙6–276∙2) ∙∙ ∙∙
Episodes (1000s) 7233 (4201–12 457) ∙∙ ∙∙ 10 162 (5902–17 502) ∙∙ ∙∙
Age 12–59 months
Studies 2 1 3 2 3 ∙∙
Incidence (per 1000 children per year) 138∙6 (57∙2–299∙4) ∙∙ 147∙3 (82∙6–248∙9) 138∙6 (57∙2–299∙4) 147∙3 (82∙6–248∙9) ∙∙
Episodes (1000s) 47 524 (20 871–108 280) ∙∙ 7467 (4315–12 926) 67 125 (29 479–152 938) 8199 (4738–14 194) 74 448 (33 844–165 089)
Age 0–59 months
Studies 8 (3)‡ 1 9 (3) 8 (3) 10 (3) ∙∙
Incidence (per 1000 children per year) 175∙2 (101∙5–302∙3) ∙∙ 61∙9 (32∙5–117∙9) 175∙2 (101∙5–302∙3) 42∙4 (17∙2–104∙8) ∙∙
Episodes (1000s) 75 538 (43 911–129 996) ∙∙ 3925 (2068–7453) 106 557 (61 943–183 376) 2953 (1202–7259) 109 510 (63 145–190 635)
Influenza virus-associated ALRI cases
Age 0–5 months
Studies 4 1 0 5 ∙∙ ∙∙
Incidence (per 1000 children per year) 4∙9 (2∙2–10∙8) ∙∙ ∙∙ 8∙5 (2∙6–26∙9) ∙∙ ∙∙
Episodes (1000s) 217 (98–479) ∙∙ ∙∙ 528 (165–1688) ∙∙ ∙∙
Age 6–11 months
Studies 4 1 0 5 ∙∙ ∙∙
Incidence (per 1000 children per year) 28 (23∙6–33∙3) ∙∙ ∙∙ 27∙6 (23∙4–32∙6) ∙∙ ∙∙
Episodes (1000s) 1229 (1036–1459) ∙∙ ∙∙ 1702 (1444–2008) ∙∙ ∙∙
Age 12–59 months
Studies 4 1 0 5 ∙∙ ∙∙
Incidence (per 1000 children per year) 16∙7 (8∙6–32∙3) ∙∙ ∙∙ 15∙6 (8∙9–27∙1) ∙∙ ∙∙
Episodes (1000s) 5727 (29 66–11 062) ∙∙ ∙∙ 7556 (4344–13 149) ∙∙ ∙∙
Age 0–59 months
Studies 7 (3)‡ 1 4 (3) 8 (3) 4 (3) ∙∙
Incidence (per 1000 children per year) 14∙6 (9∙2–23∙3) ∙∙ 9∙3 (7∙5–11∙5) 15∙6 (10∙3–23∙6) 9∙3 (7∙5–11∙5) ∙∙
Episodes (1000s) 6299 (3961–10 021) ∙∙ 590 (477–729) 9498 (6305–14 313) 648 (524–800) 10 145 (6829–15 113)
(Table 1 continues on next page)
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(UR 0∙1–1∙6) very severe influenza-virus-associated 
ALRI cases in children under 5 years in developing 
countries (table 1).
We identified 96 studies reporting influenza-virus-
associated ALRI hospital admission rates, including 
59 studies with data on age groups 0–5 months, 
6–11 months, or 12–59 months (appendix pp 37–43). 
Among children under 5 years, we estimated 
870 000 hospital admissions (UR 543 000–1 435 000) for 
influenza-virus-associated ALRI globally, of which 23% 
and 21% were in infants aged 0–5 months and 
6–11 months, respectively (table 2). An estimated 
420 000 hospital admissions for influenza-virus-
associated ALRI (UR 261 000–677 000) occurred in 
LMICs. In subgroup analyses of studies with low risk of 
bias and in analyses stratified by low or high national 
PCV coverage and by low or high national maternal HIV 
burden, the hospital admission estimates were similar to 
those in the main analysis; the point values ranged from 
772 000 to 895 000 for hospital admissions, with wide and 
overlapping URs (appendix pp 11–15).
For infants under 1 year, incidence meta-estimates of 
influenza virus episodes and of influenza-virus-associated 
ALRI cases increased with age (p for linear trend <0∙05, 
LMICs UMICs HICs Developing countries Industrialised 
countries
Global burden estimates*
(Continued from previous page)
Severe influenza virus-associated ALRI cases
Age 0–5 months
Studies 11 1 0 12 0 ∙∙
Incidence (per 1000 children per year) 4∙1 (1∙8–9∙3) ∙∙ ∙∙ 5∙1 (2∙2–11∙9) ∙∙ ∙∙
Episodes (1000s) 182 (80–411) ∙∙ ∙∙ 317 (137–733) ∙∙ ∙∙
Age 6–11 months
Studies 3 1 0 4 0 ∙∙
Incidence (per 1000 children per year) 3∙9 (1∙4–11∙1) ∙∙ ∙∙ 6∙1 (2∙2–16∙4) ∙∙ ∙∙
Episodes (1000s) 171 (61–479) ∙∙ ∙∙ 376 (139–1021) ∙∙ ∙∙
Age 12–59 months
Studies 3 1 0 4 0 ∙∙
Incidence (per 1000 children per year) 1∙2 (0∙6–2∙4) ∙∙ ∙∙ 1∙9 (0∙7–5∙1) ∙∙ ∙∙
Episodes (1000s) 412 (207–820) ∙∙ ∙∙ 920 (343–2471) ∙∙ ∙∙
Age 0–59 months
Studies 6 (3)‡ 1 0 7 (3) 0 ∙∙
Incidence (per 1000 children per year) 1∙7 (0∙9–3∙2) ∙∙ ∙∙ 2∙4 (1–5∙6) ∙∙ ∙∙
Episodes (1000s) 727 (386–1371) ∙∙ ∙∙ 1438 (612–3384) ∙∙ ∙∙
Very severe influenza virus-associated ALRI cases
Age 0–5 months
Studies 3 1 0 4 0 ∙∙
Incidence (per 1000 children per year) 0∙1 (0–122∙1) ∙∙ ∙∙ 0∙3 (0–13∙3) ∙∙ ∙∙
Episodes (1000s) 4 (0–673) ∙∙ ∙∙ 19 (0–940) ∙∙ ∙∙
Age 6–11 months
Studies 3 1 0 4 0 ∙∙
Incidence (per 1000 children per year) 0∙8 (0∙2–4) ∙∙ ∙∙ 1 (0∙3–3∙5) ∙∙ ∙∙
Episodes (1000s) 35 (8–156) ∙∙ ∙∙ 62 (18–209) ∙∙ ∙∙
Age 12–59 months
Studies 2 1 0 3 0 ∙∙
Incidence (per 1000 children per year) 0∙3 (0–2) ∙∙ ∙∙ 0∙5 (0∙1–2∙3) ∙∙ ∙∙
Episodes (1000s) 103 (5–2024) ∙∙ ∙∙ 242 (51–1152) ∙∙ ∙∙
Age 0–59 months
Studies 3 (1)‡ 1 0 4 (1) 0 ∙∙
Incidence (per 1000 children per year) 0∙5 (0∙1–2∙8) ∙∙ ∙∙ 0∙7 (0∙2–2∙7) ∙∙ ∙∙
Episodes (1000s) 211 (37–1194) ∙∙ ∙∙ 416 (105–1641) ∙∙ ∙∙
Data in parentheses are estimated uncertainty ranges.  Data were imputed using a multiple imputation approach. ALRI=acute lower respiratory infection. LMICs=lower-middle income countries. UMICs=upper-
middle income countries. HICs=high-income countries. ∙∙=not available. *Global burden estimates were developed by summing up estimates for 0–59 months by country development status classified according to 
UNICEF definition. †Incidence was estimated using generalised linear mixed models. ‡Data in parentheses are the number of imputed studies. 
Table 1: Estimates of the incidence (per 1000 children per year), and number of influenza virus episodes and influenza virus-associated ALRI cases in children under 5 years in the 
community in 2018, by World Bank income level and development status
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LMICs UMICs HICs Developing 
countries
Industrialised 
countries
Global*
Influenza virus–associated ALRI
Age 0–5 months
Studies 13 9 13 24 11 ∙∙
Rate (per 1000 children per year)† 1∙8 (1∙1–3∙1) 3∙7 (1∙8–7∙4) 4∙4 (3∙1–6∙3) 2∙8 (1∙8–4∙3) 3∙7 (2∙7–5∙3) ∙∙
Hospital admissions (1000s) 80 (48–133) 68 (34–138) 28 (20–40) 174 (113–268) 26 (18–36) 200 (131–304)
Age 6–11 months
Studies 11 8 9 21 7 ∙∙
Rate (per 1000 children per year) 1∙5 (1–2∙4) 3∙8 (1∙7–8∙3) 3∙5 (1∙4–8∙8) 2∙7 (1∙7–4∙3) 2∙6 (0∙9–7∙6) ∙∙
Hospital admissions (1000s) 66 (43–102) 70 (32–154) 22 (9–55) 166 (105–264) 18 (6–52) 185 (111–317)
Age 12–59 months
Studies 17 11 20 35 13 ∙∙
Rate (per 1000 children per year) 0∙8 (0∙5–1∙3) 0∙8 (0∙3–2) 1∙2 (0∙6–2∙2) 0∙9 (0∙6–1∙5) 0∙9 (0∙4–1∙8) ∙∙
Hospital admissions (1000s) 274 (171–441) 117 (46–301) 61 (32–116) 436 (276–688) 50 (24–106) 486 (300–794)
Age 0–59 months
Hospital admissions (1000s) 420 (261–677) 255 (111–593) 111 (60–211) 776 (494–1220) 94 (48–194) 870 (543–1415)
Influenza virus-associated ALRI with hypoxaemia
Age 0–5 months
Studies 8 2 ∙∙ 10 ∙∙ ∙∙
Rate (per 1000 children per year) 0∙9 (0∙5–1∙6) 0∙9 (0∙5–1∙5) ∙∙ 0∙9 (0∙6–1∙4) ∙∙ ∙∙
Hospital admissions (1000s) 40 (22–71) 17 (10–29) ∙∙ 56 (37–85) ∙∙ ∙∙
Age 6–11 months
Studies 8 2 ∙∙ 10 ∙∙ ∙∙
Rate (per 1000 children per year) 0∙7 (0∙3–1∙4) 1 (0∙7–1∙6) ∙∙ 0∙8 (0∙5–1∙1) ∙∙ ∙∙
Hospital admissions (1000s) 31 (14–66) 18 (12–28) ∙∙ 49 (33–73) ∙∙ ∙∙
Age 12–59 months
Studies 8 1 2 9 2 ∙∙
Rate (per 1000 children per year) 0∙2 (0∙1–0∙4) ∙∙ 0 (0–1∙3) 0∙2 (0∙1–0∙3) 0 (0–1∙3) ∙∙
Hospital admissions (1000s) 69 (34–137) ∙∙ 0 (0–4) 97 (56–167) 0 (0–4) 97 (56–172)
Age 0–59 months
Hospital admissions (1000s) 139 (71–274) ∙∙ ∙∙ 202 (126–326) 7 (1–62)‡ 209 (127–387)
Very severe influenza virus-associated ALRI
Age 0–5 months
Studies 9 3 2 12 2 ∙∙
Rate (per 1000 children per year) 0∙6 (0∙2–1∙4) 0∙2 (0∙1–0∙4) 0∙3 (0∙1–0∙7) 0∙3 (0∙1–0∙9) 0∙3 (0∙1–0∙7) ∙∙
Hospital admissions (1000s) 27 (10–70) 4 (2–7) 2 (1–5) 19 (6–56) 2 (1–6) 21 (7–61)
Age 6–11 months
Studies 9 3 2 12 2 ∙∙
Rate (per 1000 children per year) 0∙5 (0∙3–0∙9) 0∙3 (0∙1–1) 0∙1 (0–0∙6) 0∙4 (0∙2–0∙8) 0∙1 (0–0∙6) ∙∙
Hospital admissions (1000s) 22 (13–38) 6 (2–17) 1 (0–7) 25 (12–49) 1 (0–8) 25 (12–57)
Age 12–59 months
Studies 9 5 8 16 6 ∙∙
Rate (per 1000 children per year) 0∙1 (0–0∙3) 0∙1 (0–0∙2) <0∙05 0∙1 (0–0∙2) <0∙05 ∙∙
Hospital admissions (1000s) 34 (4–263) 15 (2–92) 0 (0–0) 48 (8–303) 0 (0–0) 49 (8–304)
Age 0–59 months
Hospital admissions (1000s) 83 (27–371) 24 (6–116) 3 (1–12) 92 (26–408) 3 (1–13) 95 (28–421)
Data in parentheses are estimated uncertainty ranges. ALRI=acute lower respiratory infection. LMICs=lower-middle income countries. UMICs=upper-middle income countries. 
HICs=high-income countries. ∙∙=not available. *Global burden estimates were developed by summing up estimates in three non-overlapping age groups (0–5 months, 
6–11 months, and 12–59 months), and in developing and industrialised countries classified according to UNICEF definition. †Hospital admissions rates were estimated using 
generalised linear mixed models. ‡In industrialised countries, two studies reported the hospital admission rates for influenza virus-associated ALRI with hypoxaemia for 
0–59 months; the meta-estimate was 0∙1 (<0∙05–0∙4), translating to 7000 (UR 1000–62 000) hospital admissions.
Table 2: Estimates of hospital admission rates (per 1000 children per year), and number of hospital admissions in children under 5 years with influenza 
virus-associated ALRI in 2018, by World Bank income level and development status
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appendix p 67). The linear trend for hospital admission 
rates was not significant. However, the hospital admission 
rate of influenza-virus-associated ALRI was lower in 
neonates (0∙9 per 1000 neonates per year, 95% CI 0∙4–1∙8), 
and was consistently higher in infants older than 1 month 
(1∙6–1∙9 per 1000 infants per year) in developing countries. 
Only two studies reported hospital admission rates of 
influenza-virus-associated ALRI by narrow age groups 
among infants in industrialised countries.
Based on 15 studies, we estimated 209 000 hospital 
admissions for influenza-virus-associated ALRI with 
hypoxaemia (UR 127 000–387 000) globally in children 
under 5 years. An estimated 139 000 (UR 71 000–274 000) 
hospital admissions occurred in LMICs (table 2). For 
very severe influenza-virus-associated ALRI, based on 
24 studies, we estimated 95 000 (UR 28 000–421 000) 
hospital admissions in children under 5 years globally, 
22% and 26% in infants aged 0–5 months and 
6–11 months, respectively (table 2). An estimated 83 000 
(UR 27 000–371 000) hospital admissions for very severe 
influenza-virus-associated ALRI occurred in LMICs.
66 studies reported hCFRs for influenza-virus-
associated ALRI in children under 5 years, including 
28 studies with data on three non-overlapping age 
bands (appendix pp 49–53). We estimated that hCFRs 
for influenza-virus-associated ALRI were 3∙1% (95% CI 
1∙3–6∙9), 2∙0% (0∙6–6∙2), and 1∙4% (0∙7–2∙8) in 
children aged 0–5 months, 6–11 months, and 
12–59 months in developing countries, respectively 
(table 3). By country-income group, hCFRs were higher 
in LMICs (3∙4%, 95% CI 1∙4–7∙9, for 0–59 months) 
than UMICs (1∙4%, 0∙6–3∙5) and HICs (0∙5%, 0∙2–1∙4). 
The analysis stratified by age and country develop-
ment status yielded 15 300 influenza-virus-associated 
ALRI (UR 5800–43 800) in-hospital deaths in children 
under 5 years, with 36% and 23% among infants aged 
0–5 months and 6–11 months, respectively. About 
82% of influenza-virus-associated ALRI in-hospital 
deaths occurred in LMICs. We did stratified analyses in 
studies with low risk of bias, by low or high national 
PCV coverage and by low or high maternal HIV burden. 
In these sensitivity analyses, in-hospital mortality 
estimates were similar to those in the main analysis; the 
point values ranged from 13 800 to 20 800 for in-hospital 
mortality, with wide and overlapping URs (appendix 
pp 12–13, 16–17).
For industrialised countries, we estimated an inflation 
factor of 1∙6 (range 1∙3–1∙9 across 14 years) based on the 
data for US paediatric influenza-virus-associated deaths. 
For developing countries, we used an inflation factor of 
2∙3 in the main analysis (range 1∙5–3∙5 across six sites), 
and estimated an overall influenza-virus-associated ALRI 
mortality of 34 800 (UR 13 200–97 200) in children under 
5 years globally. In sensitivity analyses, we estimated a 
higher inflation factor in approach 2 (3∙0) and 
approach 3 (3∙4). Using the two approaches, the point 
overall mortality estimate could increase by 30–47%, with 
wide and overlapping URs (appendix pp 20–26).
Discussion
We estimated that globally in 2018, in children under 
5 years, there were 109∙5 million influenza virus 
episodes, around 10 million cases of influenza-virus-
associated ALRI, about 870 000 hospital admissions 
for influenza-virus-associated ALRI, 15 000 in-hospital 
deaths from influenza-virus-associated ALRI, and around 
35 000 total deaths from influenza-virus-associated ALRI. 
The wide uncertainty ranges of the burden estimates 
reflected differences across studies, arising from the 
variation in influenza activity between seasons, variation 
LMICs UMICs HICs Developing countries Industrialised 
countries
Global*
Studies† 10 11 7 23 5 ∙∙
Age 0–5 months
hCFR (%)‡ 3∙2 (0∙6–15∙4) 2∙6 (0∙9–7∙5) 0∙5 (0–4∙6) 3∙1 (1∙3–6∙9) 0∙3 (0–6∙9) ∙∙
Deaths 2500 (500–13 800) 1800 (500–6200) 100 (0–4100) 5400 (2100–13 700) 100 (0–2700) 5500 (2100–16 300)
Age 6–11 months
hCFR (%) 8∙1 (4∙1–15∙3) 0∙7 (0∙1–7∙4) 0∙8 (0∙2–3∙2) 2∙0 (0∙6–6∙2) 0∙9 (0∙2–3∙4) ∙∙
Deaths 5300 (2400–11 600) 500 (0–4700) 200 (0–900) 3300 (900–11 500) 200 (0–900) 3500 (1000–12 400)
Age 12–59 months
hCFR (%) 3∙3 (1∙7–6∙3) 0∙8 (0∙3–2∙2) 0∙4 (0∙1–2∙1) 1∙4 (0∙7–2∙8) 0∙4 (0∙1–2∙7) ∙∙
Deaths 9100 (4000–20 100) 900 (200–3700) 200 (0–1300) 6100 (2700–13 800) 200 (0–1200) 6300 (2700–14 900)
Age 0–59 months
Deaths 17 000 (6900–45 100) 3200 (800–14 400) 600 (100–6200) 14 800 (5700–39 000) 500 (100–4800) 15 300 (5800–43 800)
Data in parentheses are estimated uncertainty ranges. ALRI=acute lower respiratory infection. LMICs=lower-middle income countries. UMICs=upper-middle income 
countries. HICs=high-income countries. ∙∙=not available. *Global estimates were calculated by summing up estimates in three non-overlapping age groups (0–5 months, 
6–11 months, and 12–59 months), and in developing and industrialised countries according to UNICEF definitions. †hCFR meta-estimates were based on studies providing 
data for the three non-overlapping age bands. ‡hCFRs were estimated using generalised linear mixed models.
Table 3: In-hospital case fatality ratio (hCFR) meta-estimates and in-hospital deaths in children under 5 years with influenza virus-associated ALRI in 
2018, by World Bank income level and development status
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in influenza epidemiology between populations and 
methodological differences, and lack of data, especially 
mortality data.
The incidence rates of influenza virus episodes and 
influenza-virus-associated severe ALRI in children under 
5 years were consistent with our previous estimates 
for 2008.5 However, we estimated a lower incidence 
of influenza-virus-associated ALRI compared with the 
previous review for 0–59 months in developing countries. 
In the previous review, the incidence of influenza-
virus-associated ALRI was only based on three studies 
from two sites. Our updated estimate was refined by 
incorporating new data with larger sample sizes achieved 
by multiple-season observation and data from more 
geographically diverse areas (12 studies). Improved 
influenza vaccine uptake is not likely to be the reason for 
the lower incidence of influenza-virus-associated ALRI 
since paediatric influenza immunisation policy had not 
been introduced (in Bangladesh, India, and Pakistan), or 
was only introduced in children with chronic diseases (in 
Nicaragua), or achieved low coverage (in South Africa) 
during the study periods.36 The national PCV coverage 
was above 60% midway in three studies in Nicaragua, 
Pakistan, and South Africa; increase in PCV uptake 
might contribute to the lower point value of incidence 
rates.26,37 The reduction in influenza-virus-associated 
ALRI incidence rates is consistent with a general decrease 
in the incidence of all-cause ALRI.2 Our estimate of 
influenza-virus-associated ALRI cases, after accounting 
for the attributable fraction of influenza virus in 
influenza-virus-associated ALRI (80%), generally agreed 
with the number of influenza-virus-attributable ALRI 
cases (about 8 million) estimated by the Institute for 
Health Metrics and Evaluation (IHME).
We estimated about 870 000 influenza-virus-associated 
ALRI hospitalisations (about 5% of all-cause hospitalised 
ALRI), similar to our previous estimate.5,38 Our estimate 
developed using an incidence-based approach, is lower 
than the IHME estimate of influenza-virus-attributable 
ALRI hospitalisations for 2017 (about 2 200 000) derived 
from a proportion-based approach.39 The difference in the 
two estimates might reflect the difference in analytical 
methods; data used in the two analytical methods were 
not directly comparable. Nevertheless, a previous study 
reported an estimate similar to our result, although using 
a proportion-based approach.4 Our global estimates for 
influenza-virus-associated ALRI hospitalisations changed 
marginally (if at all) in sensitivity analyses, suggesting 
that they were not affected by study biases, or inclusion of 
data from different settings—eg, with different PCV 
coverages and HIV burden. The primary objective of 
doing these sensitivity analyses was to assess to what 
extent the global estimates would be affected by these 
factors. It is important to note that the estimates in the 
stratified analyses by PCV coverage (and by 2009) were 
not directly comparable because most data were from 
different areas. We identified five studies reporting 
influenza-virus-associated ALRI hospitalisation rates for 
at least 5 consecutive years with PCV introduced midway. 
In a pooled regression analysis of the five studies, we did 
not find a significant difference in influenza-virus-
associated ALRI hospitalisation rates between high PCV 
coverage periods and low coverage periods. However, this 
finding needs to be interpreted with caution because the 
five studies had short observation periods (5–8 years). In 
the main analyses of influenza-virus-associated ALRI 
hospitalisations, most studies were from the post-2009 
period, and hospitalisation estimates did not change after 
excluding pre-2009 data. Moreover, the estimate did not 
change after excluding 2010 data, when the influenza 
pandemic affected some regions.40 80% of influenza-
virus-associated ALRI can be attributed to influenza 
based on a systematic review of case-control studies 
investigating the viral profile in children under 5 years 
with and without ALRI. Thus, based on our estimate, 
696 000 ALRI hospitalisations could be attributed to 
influenza virus in children under 5 years.41
We estimated 15 300 influenza-virus-associated ALRI 
in-hospital deaths based on 28 hCFR studies. The 
estimates were not affected by risk of bias or by the 
inclusion of data from different PCV coverage settings 
and HIV burden settings. We estimated up to 4% of all 
childhood ALRI deaths were associated with influenza 
virus.2 Our estimate was between the IHME influenza-
virus-attributable ALRI mortality estimate (about 
23 400 influenza-virus-attributable ALRI deaths in 2017) 
and the influenza-virus-associated respiratory mortality 
estimate in a study by Iuliano and colleagues (44 888, 
95% credible interval 9243–105 690, in 2015) for 
92 countries where 92% of respiratory deaths occurred.39,42 
The IHME mortality estimate was modelled on all-cause 
ALRI deaths, the percentage of influenza virus in patients 
with ALRI from published literature, the attributable 
fraction of influenza virus for influenza-virus-confirmed 
ALRI, and the ratio of case-fatality between viral ALRI 
and bacterial ALRI (viral-to-bacterial case fatality ratio).39 
Iuliano and colleagues did a time series analysis using 
records for vital respiratory deaths and influenza 
circulation data in three countries, and extrapolated these 
to other countries. The different estimates in the 
two studies reflected the difference in case definitions 
(respiratory deaths vs ALRI deaths) and in statistical 
models;43 we used three different approaches to model 
the number of overall deaths, and reported the most 
conservative influenza-virus-associated ALRI mortality 
burden.
For calculation of the upper bound of influenza-virus-
associated ALRI mortality (overall influenza-virus-associ-
ated ALRI mortality), we estimated a more conservative 
inflation factor (2∙3) for developing countries in the 
main analysis than those used in another two approaches 
in sensitivity analyses (3∙0 in approach 2 and 3∙4 in 
approach 3). Each approach has potential biases. 
One modelling study in South Africa estimated that 
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a significantly higher percentage of influenza-virus-
attributable deaths occurred outside hospitals than the 
percentage of all-cause deaths occurring outside hospitals 
(57% versus 41%).44 This finding suggests that using the 
inflation factor for all-cause pneumonia might under-
estimate the influenza-virus-specific estimate in the main 
analysis. Potential biases for approaches 2 and 3 are 
explained in the appendix, pp 20–24. Although estimated 
using data from six sites, the estimated inflation factor 
was still limited by lack of data. Health-care access varies 
significantly across the world; most data we included 
were from rural areas and from LMICs. The inflation 
factor and the upper bound of mortality estimate in 
developing countries might be overestimated due to the 
poor access to health care at these sites. Care-seeking has 
been investigated in national household surveys of 
11 Middle East and North African countries: 34–80% 
(median 70% approximately) of children under 5 years 
with acute respiratory infec tions (caregiver’s self-report) 
sought care in health facilities.45 However, it is still 
challenging to understand the scenario of ALRI deaths 
from these data. For industrialised countries, we 
estimated the inflation factor using mortality data for 
0–17 years, which might cause an underestimation if 
young children are more likely to die before being 
admitted, or an overestimation if young children are 
more likely to be taken to health-care facilities when they 
are sick.46
We estimated the highest hCFRs in LMICs, and 82% of 
the in-hospital deaths occurred in these countries. 
However, only 10% of LICs and LMICs have had a 
national policy for influenza immunisation in children 
(13% for pregnant women) in 2014.9 Where present there 
were mostly very low or unknown levels of vaccine 
coverage.6,47–50 According to previous evidence, a high 
influenza vaccine coverage (about 70%) can substantially 
reduce influenza-associated hospitalisations and deaths 
in children under 5 years of age.51
A large proportion of influenza-virus-associated ALRI 
hospitalisations (44%) and in-hospital deaths (59%) 
occurred during infancy, with 23% of hospitalisations and 
36% of the in-hospital deaths in infants under 6 months. 
Our estimates of influenza-virus-associated ALRI hospitali-
sations are likely to underestimate the effect of influenza. 
Influenza can cause primary infections or expose children 
to severe secondary bacterial infections while not being 
detected at specimen collection. Maternal influenza 
vaccination trials assessing vaccine efficiency against 
hospitalised ALRI might help to understand the direct 
and indirect effects of influenza in causing ALRI.52,53 The 
infant data we included were from developing countries 
with either no influenza immuni sation policy or low 
influenza vaccine coverage in pregnant women during the 
study periods (ie, Bangladesh, Guatemala, India, Kenya, 
Mozambique, South Africa, and Thailand).36,54,55 Findings 
from two trials in Mali and South Africa suggested 
that maternal influenza immunisation is an effective 
intervention against influenza infections in the first 
3 months of age.56,57 Influenza virus predisposes individuals 
to secondary bacterial infection and adverse outcomes 
associated with such infections.58 Therefore, preventing 
influenza virus through maternal immuni sation could 
play a role in reducing the burden of all-cause ALRI. For 
example, in a pooled analysis of three maternal influenza 
immunisation trials in South Africa, Mali, and Nepal, 
there was a 20% reduction in all-cause severe clinical 
pneumonia in infants under 6 months.53 However, there 
was heterogeneity in this effect between three trials; 
therefore, it would be challenging to quantify the global 
effect of maternal influenza immunisation on reducing 
all-cause ALRI in early infancy.
Our burden estimates were generally robust to the 
sensitivity analyses we performed. However, there were 
some limitations in our review. First, although we pre-
specified case definitions, heterogeneity between studies 
still existed; for example, 50% of hospital-based 
studies used other definitions (eg, hospitalised acute 
respira tory infection). This might cause an over estimation 
of influenza-virus-associated ALRI hospitalisations. 
Second, PCR was used in about 70% of hospital-based 
studies to detect influenza, and diagnostic tools with 
lower sensitivity were used in 30% of studies. However, 
the hospitalisation estimates did not change when 
restricting the analysis to these PCR studies. Third, not 
all infections were tested for influenza virus. For 
incidence and hospitalisation rates, we have adjusted for 
underdetection, assuming the proportion of influenza 
virus in tested and untested cases was the same. Studies 
were systematically assessed, and the rates might have 
been biased in some studies: for influenza-virus-
associated ALRI hospitalisation rates, at least 90% of 
eligible cases were tested in 50% of studies; less than 
90% of cases were tested in 30% of studies, and the main 
reasons for not collecting specimens included cases being 
tested systematically (17%), refusal and discharge (10%), 
and unknown reasons (3%); in the remaining 20% of 
studies the proportion tested was unavailable. We 
reported unadjusted hCFRs, which might be under-
estimated because children who were very ill were less 
likely to be sampled and tested, as suggested by the higher 
hCFRs among untested cases than those tested (appendix 
p 26). Fourth, hospitalisation estimates were affected by 
access to health care and health-seeking behaviour, so the 
potential numbers of influenza-virus-associated ALRI 
hospitalisations are likely to be higher in resource-limited 
areas and in older children who are less likely to be taken 
to health-care facilities when they are sick.46 Furthermore, 
influenza vaccine coverage has increased over the last 
decade in industrialised countries (eg, in the USA). 
Estimates based on data during the low vaccine coverage 
period could cause an overestimation. Due to the scarcity 
of influenza vaccine coverage data in most countries, we 
determined not to adjust influenza vaccine use in 
estimating influenza-associated burden.
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Based on 157 studies of which 123 studies were not 
included in our 2008 estimates, we reported the new 
estimates in the era with the circulation of 
influenza A/H1N1pdm09. Although we included more 
studies than our previous review, estimates were still 
based on limited data. High-quality in-hospital mortality 
data, especially from LICs, are needed to improve the 
global in-hospital mortality estimate. Studies reporting 
age-stratified influenza-virus-associated ALRI morbidity 
and mortality burden should be encouraged. Moreover, 
further influenza-virus-associated ALRI mortality studies 
should ensure optimal sample size for robust mortality 
estimation. These efforts will help refine estimates of 
global burden of influenza in young children and 
understand the role of influenza in childhood disease, and 
inform policy. The initiation of post-mortem surveillance 
such as in the Child Health and Mortality Prevention 
Surveillance Network, will provide evidence to improve 
influenza-virus-associated mortality estimation.59
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